Skip to contentP
Panacea Life Sciences Holdings, Inc.
P
PLSHPanacea Life Sciences Holdings, Inc. Q3 2021 · 10-Q
Revenue$588.04K$588.04K−56.2% vs Q3 2020 Net Income-$3.09M-$3.09MN/M vs Q3 2020 EPS Diluted-$0.14-$0.14N/M vs Q3 2020 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Panacea Life Sciences Holdings, Inc. · CIK 1552189 · Engraved from SEC EDGAR
Operating Cash Flowderived-$752,504N/M Free Cash Flowderived-$738,704N/M Margins · derivedGross margin48.1%+164.4 pt vs Q3 2020
Operating margin-213.9%+35.3 pt vs Q3 2020
Net margin-525.4%−244.1 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 22, 2021 · 53 d after period end